At Nouvogenes Therapeutics, our research is centered on advancing the frontiers of gene editing to develop next-generation therapies for serious and underserved diseases. We harness the power of CRISPR/Cas systems—one of the most transformative innovations in molecular biology—to precisely edit the genome or transcriptome at the root of disease.

The CRISPR platform enables highly efficient and accurate modification of DNA or RNA using programmable nucleases guided by RNA. By leveraging the body’s natural repair mechanisms—such as homologous recombination and non-homologous end joining—we can achieve targeted gene correction, disruption, activation, or silencing. These capabilities form the basis of our therapeutic programs and open the door to treating a wide range of genetic and complex diseases.

Our scientific efforts span both DNA and RNA editing technologies, including clinically relevant systems such as Cas9, Cas12, and Cas13. We are actively developing and refining proprietary gene editing tools with enhanced precision, minimized off-target effects, and superior delivery potential. Our research pipeline includes applications in gene knock-in, base editing, epigenetic modification, and gene activation—all aimed at unlocking lasting therapeutic impact.

Nouvogenes Therapeutics is committed to addressing high-burden diseases such as transfusion-dependent thalassemia, hemophilia, inherited retinal disorders, and other complex conditions including cardiovascular, autoimmune, neurodegenerative diseases, and cancer. With a focus on clinical unmet needs, we aim to deliver safe, effective, and scalable gene therapies that can change the course of disease and restore health for millions worldwide.

We appreciate your interest in our mission to advance curative gene therapies. A member of our team will respond to your message as soon as possible.
Thank you for connecting with Nouvogenes Therapeutics.